This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. ADCs have the potential to redress the poor balance between safety and efficacy seen with traditional cancer treatment options.
Institute of OrganicChemistry and Biochemistry of the AS CR, v.v.i. Bavtavirine is part of highly active antitiretroviral therapy (HAART) treatment regimen. Benzonitrile, 4-[[4-amino-8-[4-[(1 E )-2-cyanoethenyl]-2,6-dimethylphenyl]-2-quinazolinyl]amino]- Gilead Sciences, Inc.;
How have advancements in antibody-drug conjugates (ADCs) expanded treatment options for different types of cancer? For example, enfortumab vedotin in combination with anti-PD-1 pembrolizumab reshaped the first-line treatment of patients with previously untreated metastatic urothelial cancer, doubling OS compared to standard of care.
After completing my PhD in organicchemistry at the University of Cambridge, I went to Canada as a Leverhulme Trust postdoctoral fellow. For example, there are often many potential targets you could consider developing a treatment against for a given disease; how do you choose between them? I’m a chemist by training.
A graduate of the Hebrew University of Jerusalem, he earned a Bachelor of Science in chemistry and physics and a Master of Science in physical organicchemistry before completing a Doctor of Philosophy in 1971. Dr. Elmaleh has contributed to more than 130 book chapters, scientific papers, and professional journal articles.
Coupling my desire to be a scientist with my keen sense of adventure, I moved to Alaska out of high school to begin my undergraduate studies in chemistry, applying myself to my STEM classes whilst also climbing mountains and chasing Northern Lights.
If they are detected shortly after birth with a few drops of blood from the heel, treatment is possible. Adding these two conditions, experts say, would identify 400 to 450 babies a year whose lives could be saved, with gene therapy. That’s the case for some gene therapies. But it must begin ASAP.
An important research area at AbbVie involves blood cancers, where our ultimate goal is to transform standards of care across these diseases and advance a dynamic cancer research and treatment pipeline. 2 However, treatment options were still limited and often came with severe side effects.
As Executive Director of CMC Regulatory Affairs at Biohaven , she leads efforts to develop innovative therapies from the clinic to market approval. Throughout her career, Bakrania has held pivotal roles at renowned companies, including Biohaven, where she contributed to the development of therapies, such as migraine treatment Nurtec ODT.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content